GlassScriptPhysician profile
Beena Khetpal
NPI 1568497477
$818.44
in general payments reported to CMS, 2019-2025
20 companies · $170 in 2025
The $170 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2021: $36.22 · 2022: $44.21 · 2023: $197 · 2024: $143 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $509.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $171.31 | 2019-2025 | Bexsero, Menveo, Arexvy |
| Merck Sharp & Dohme LLC | $137.22 | 2023-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Cranial Technologies, INC | $89.28 | 2019-2025 | Doc Band |
| Ucb, INC. | $60.67 | 2019-2023 | Briviact |
| Abbvie INC. | $55.69 | 2019-2024 | |
| Pfizer INC. | $33.84 | 2023-2025 | |
| Neurelis, INC. | $33.39 | 2025 | Valtoco |
| Astrazeneca Pharmaceuticals LP | $22.49 | 2025 | Tezspire |
| Ironshore Pharmaceuticals INC. | $21.82 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $20.76 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.60 | 2023 | Nuedexta |
| Shire North American Group INC | $19.59 | 2019 | |
| Eisai INC. | $17.66 | 2023 | |
| Sobi, INC | $17.53 | 2023 | |
| Sanofi Pasteur INC. | $17.34 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $16.85 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.50 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $16.01 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.46 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.43 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beena Khetpal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.